BNGO Bionano Genomics Inc

$BNGO The worst investment of my life, not much but still criminal. This company should vanish from the earth .

$BNGO $PACB PacBio tried to bury the FSHD map. Their own data does not do it. Oct 8 post is Kivvi, a HiFi tool for the D4Z4 repeat. It called 11 of 11 contracted alleles, checked against Southern blot on 27 controls and OGM on 10 GeneDx FSHD1 samples. A tool paper. Then the pitch: OGM is slow, blood only, wait for a batch, no methylation, so buy the sequencer. Stratys does not batch. Twelve single-sample chips. Load one. Unload it when it finishes. The slow part is the DNA prep. Ionic fixes that. Isotachophoresis, eight samples, about two hours, already shown pulling OGM-grade DNA from blood and marrow. Methylation is the one they have. OGM does not call 5mC. FSHD2 still wants it. OGM’s job is the blot’s job: repeat count, haplotype, 4 versus 10. EnFocus is 100% concordant with Southern blot on that count. A methylation number does not replace the map. It sits next to it.

$BNGO Bionano Laboratories just posted for a Clinical Lab Director. Board-certified pathologist/lab geneticist. On-site San Diego. CLIA/CAP lab oversight. Explicit MolDX technical assessment experience required. Preferred OGM knowledge. Responsibilities include sign-out of clinical diagnostic OGM data for heme and constitutional cases, integrating OGM with FISH/CMA/NGS, and direct support for MolDX, Medicare contractors, and payers. This is the services side staffing the lab that sits behind 81195 ($1,853.22) and 81354. Draft MolDX LCD is already out. NYSDOH LDTs are live. They’re hiring the person who can sign the cases and speak the reimbursement language. Paid codes only turn into volume once the CLIA lab is staffed to run them. This is that step.

$BNGO ASHG 2026: Bionano previewing automated first step of OGM workflow (upstream of chip load) to industrialize prep. Booth #810. Meet-the-Expert w/ Alexander Hoischen (Radboudumc) Thu 3:30–4:30. Stratys/Saphyr/VIA on floor. Hoischen’s group already published OGM in heme, constitutional & large repeats; prior work showed automated UHMW isolation (Hamilton) preserves length + cuts hands-on time. Front-end automation is the remaining bottleneck for higher-volume labs. Demand already outpaces flow-cell supply. Routine sites drive consumable pull-through. Live 81195 ($1,853.22) + 81354, MolDX proposed LCD open, NYSDOH at Rochester + MSK. Walk-away prep lets the same installed base run more samples without linear headcount. Utilization compounds on boxes already in the field.

$BNGO Sources say, Erik Holmlin resigned due to complications with his most recent “ARS” (Anal Reconstruction Surgery). His aDickshun to Phalus shaped Peloton accessories got completely out of control. Not judging………

$BNGO in a nutshell: 🔬 World-class technology (OGM adoption growing) ⏳ Reimbursement timeline: 2-4 years to full standard-of-care 💸 Cash burn vs. runway is the key risk ​The tech is real, but cash is running out very soon. So more dillution or a buyer is making good business.

$BNGO Laughing my ballz off. The remedial poster Punk was laughing because BNGO was trading higher thanPACB last month. BNGO will never be profitable another dilutive raise shortly and then another (3rd) reverse split. Dump this trash and buy the future of genomics Hi Fi Long Read Pacific Biosciences. PACB baybee!

$BNGO It's highly likely that the company will raise the much needed cash by lowering the warrants conversion price from$2 to 1 while issuing additional warrants with a new conversion price of $1.